Paul Buderath
Overview
Explore the profile of Paul Buderath including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1505
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Tserpeli V, Stergiopoulou D, Londra D, Giannopoulou L, Buderath P, Balgkouranidou I, et al.
Cancers (Basel)
. 2022 Jan;
14(1).
PMID: 35008168
Background: Epigenetic alterations in ctDNA are highly promising as a source of novel potential liquid biopsy biomarkers and comprise a very promising liquid biopsy approach in ovarian cancer, for early...
12.
Buderath P, Stukan M, Ruhwedel W, Strutas D, Feisel-Schwickardi G, Wimberger P, et al.
J Gynecol Oncol
. 2021 Dec;
33(1):e9.
PMID: 34910390
Objective: The surgical concept of total mesometrial resection (TMMR) and therapeutic lymphadenectomy (tLNE) for the treatment of early cervical cancer is based on the ontogenetic cancer field model. Unicentric data...
13.
Mach P, Kimmig R, Kasimir-Bauer S, Buderath P
Front Oncol
. 2021 Nov;
11:721067.
PMID: 34778036
Introduction: Epithelial ovarian cancer (EOC) is the deadliest gynecologic malignancy worldwide. Reliable predictive biomarkers are urgently needed to estimate the risk of relapse and to improve treatment management. Soluble immune-checkpoints...
14.
Stukan M, Buderath P, Szulczynski B, Gebicki J, Kimmig R
Diagnostics (Basel)
. 2021 Oct;
11(10).
PMID: 34679447
We aimed to evaluate the accuracy of ultrasonography with gynecologic examination performed by a gynecological oncologist and magnetic resonance imaging (MRI) interpreted by a radiologist for the local and regional...
15.
Salmon C, Levermann J, Neves R, Liffers S, Kuhlmann J, Buderath P, et al.
Cancers (Basel)
. 2021 Aug;
13(15).
PMID: 34359649
In Ovarian Cancer (OC), the analysis of single circulating tumor cells (sCTCs) might help to investigate genetic tumor evolution during the course of treatment. Since common CTC identification features failed...
16.
Hasenburg A, Plett H, Kramer B, Braicu E, Czogalla B, Bossart M, et al.
Arch Gynecol Obstet
. 2021 Jul;
304(6):1541-1549.
PMID: 34287678
Purpose: Malignant ovarian germ cell (MOGCT) and sex cord stromal tumors (SCST) are ovarian neoplasms that affect disproportionally young women. Little is known about the impact of surgical and adjuvant...
17.
Buderath P, Rusch P, Mach P, Kimmig R
J Gynecol Oncol
. 2020 Nov;
32(1):e7.
PMID: 33185048
Objective: Peritoneal mesometrial resection (PMMR) plus targeted compartmental lymphadenectomy (TCL) aims at removal of the locoregional cancer field in endometrial cancer (EC). Optimal locoregional control without adjuvant radiotherapy and acceptable...
18.
Mach P, Kimmig R, Buderath P
Minerva Ginecol
. 2020 Nov;
72(6):399-403.
PMID: 33140629
Lymph node involvement is an important prognostic factor in early and advanced epithelial ovarian cancer (EOC). However, to date there is no reliable method of detecting lymph node involvement, apart...
19.
Melnikova M, Wauer U, Mendus D, Hilger R, Oliver T, Mercer K, et al.
Mol Oncol
. 2020 Feb;
14(4):686-703.
PMID: 32037720
Platinum-based compounds remain a well-established chemotherapy for cancer treatment despite their adverse effects which substantially restrict the therapeutic windows of the drugs. Both the cell type-specific toxicity and the clinical...
20.
Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R, et al.
N Engl J Med
. 2019 Dec;
381(25):2416-2428.
PMID: 31851799
Background: Olaparib has shown significant clinical benefit as maintenance therapy in women with newly diagnosed advanced ovarian cancer with a mutation. The effect of combining maintenance olaparib and bevacizumab in...